Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Rongchang Chen, Nanshan Zhong, Hao-Yan Wang, Li Zhao, Xiaodong Mei, Zhiqiang Qin, Juan Huang, Pryseley N Assam, Andrea Maes, Shahid Siddiqui, Ubaldo J Martin & Colin Reisner. (2020) Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 43-56.
Read now
Read now
Nanshan Zhong, Jinping Zheng, Sang Haak Lee, David A Lipson, Xin Du & Shunquan Wu. (2020) Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 809-819.
Read now
Read now
Chenxi Li, Wenke Cheng, Jin Guo & Wei Guan. (2019) Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 799-808.
Read now
Read now
Timothy E Albertson, Willis S Bowman, Richart W Harper, Regina M Godbout & Susan Murin. (2019) Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1251-1265.
Read now
Read now
Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera, Nicola di Daniele, Andrea Girolami, Mario Cazzola & Josuel Ora. (2019) Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 20:6, pages 737-750.
Read now
Read now
Antonio Molino, Giovanna Calabrese & Mauro Maniscalco. (2018) Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol. Patient Preference and Adherence 12, pages 993-1001.
Read now
Read now
Jinping Zheng, Nanshan Zhong, Changzheng Wang, Yijiang Huang, Ping Chen, Limin Wang, Fuxin Hui, Li Zhao, Haoyan Wang, Linda Luo, Xin Du, Aik Han Goh & David A. Lipson. (2018) The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial). COPD: Journal of Chronic Obstructive Pulmonary Disease 15:4, pages 334-340.
Read now
Read now
Mohamed Ismail Abdul Aziz, Ling Eng Tan, David Bin-Chia Wu, Fiona Pearce, Gerald Seng Wee Chua, Liang Lin, Ping-Tee Tan & Kwong Ng. (2018) Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3203-3231.
Read now
Read now
Amnon Ariel, Alan Altraja, Andrey Belevskiy, Piotr W Boros, Edvardas Danila, Matjaz Fležar, Vladimir Koblizek, Zvi G Fridlender, Kosta Kostov, Alvils Krams, Branislava Milenkovic, Attila Somfay, Ruzena Tkacova, Neven Tudoric, Ruxandra Ulmeanu & Arschang Valipour. (2018) Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 45-56.
Read now
Read now
Paola Rogliani, Maria Gabriella Matera, Josuel Ora, Mario Cazzola & Luigino Calzetta. (2017) The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 3469-3485.
Read now
Read now
Jadwiga A Wedzicha, Nanshan Zhong, Masakazu Ichinose, Michael Humphries, Robert Fogel, Chau Thach, Francesco Patalano & Donald Banerji. (2017) Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 339-349.
Read now
Read now
Nicola A Hanania, Suzanne C. Lareau & Barbara P. Yawn. (2017) Safety of inhaled long-acting anti-muscarinic agents in COPD. Postgraduate Medicine 129:5, pages 500-512.
Read now
Read now
Articles from other publishers (13)
Mingjin Yang, Yishi Li, Youfan Jiang, Shuliang Guo, Jian-Qing He & Don D. Sin. (2023) Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. European Respiratory Journal 61:2, pages 2200302.
Crossref
Crossref
Yiwen Gong, Yinghua Lv, Hongxia Liu, Qingshan Zheng & Lujin Li. (2022) Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD. Therapeutic Advances in Respiratory Disease 16, pages 175346662110660.
Crossref
Crossref
Paola Rogliani, Maria Gabriella Matera, Beatrice Ludovica Ritondo, Ilaria De Guido, Ermanno Puxeddu, Mario Cazzola & Luigino Calzetta. (2019) Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulmonary Pharmacology & Therapeutics 59, pages 101841.
Crossref
Crossref
Jinchun Wu, Yi Ye, Chenxi Li, Wenqin Zhou & Rong Chang. (2019) Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD. Journal of Cardiovascular Pharmacology 74:3, pages 255-265.
Crossref
Crossref
François Maltais, Gary T. Ferguson, Gregory J. Feldman, Gaëtan Deslee, Arnaud Bourdin, Harald Fjällbrant, Agnieszka Siwek-Posłuszna, Martin A. Jenkins & Ubaldo J. Martin. (2019) A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. Advances in Therapy 36:9, pages 2434-2449.
Crossref
Crossref
Usman Maqsood, Terence N Ho, Karen Palmer, Fiona JR Eccles, Mohammed Munavvar, Ran Wang, Iain Crossingham & David JW Evans. (2019) Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
Chin Kook Rhee, Hajime Yoshisue & Rahul Lad. (2019) Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. Advances in Therapy 36:3, pages 495-519.
Crossref
Crossref
Mohd Kashif Siddiqui, Pragya Shukla, Martin Jenkins, Mario Ouwens, Deniz Guranlioglu, Patrick Darken & Mousumi Biswas. (2019)
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
2
-agonist fixed-dose combinations in COPD
. Therapeutic Advances in Respiratory Disease 13, pages 175346661989450.
Crossref
Crossref
Yuji Oba, Edna Keeney, Namratta Ghatehorde & Sofia Dias. (2018) Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Marc Miravitlles, Seungjae BaekVatsal VithlaniRahul Lad. (2018)
Optimal Bronchodilation for COPD Patients: Are All Long-Acting β
2
-Agonist/Long-Acting Muscarinic Antagonists the Same?
. Tuberculosis and Respiratory Diseases 81:3, pages 198.
Crossref
Crossref
Koichi ANDO, Akihiko TANAKA, Sojiro KUSUMOTO, Toshimitsu YAMAOKA, Tohru OHMORI, Tsukasa OHNISHI, Shin INOUE & Hironori SAGARA. (2018) Efficacy and Safety of Long-acting Beta-2 Agonist and Long-acting Muscarinic Antagonist Combinations in Patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Phase 3 Randomized Trials. The Showa University Journal of Medical Sciences 30:2, pages 159-174.
Crossref
Crossref
Cheng-Liang Qian & Rong Fan. (2017) Effect of Pingchuan Guben decoction on patients with chronic obstructive pulmonary disease: Results from a randomized comparative effectiveness research trial. Experimental and Therapeutic Medicine 14:4, pages 3915-3925.
Crossref
Crossref
Han Ni, Aung Htet & Soe Moe. (2017) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2017:6.
Crossref
Crossref